What's Happening?
AbbVie's migraine drug, Aquipta, has been approved by the NHS in England and Wales for the acute treatment of migraines. This approval follows the recent MHRA clearance and adds to its existing use for migraine prevention. The decision by NICE allows
Aquipta to be used in patients who have not responded to at least two triptan medications or cannot tolerate them. The approval is based on the ECLIPSE Phase 3 study, which showed significant pain relief in patients. The Migraine Trust has welcomed the decision, emphasizing the need for consistent access to this treatment across healthcare settings.
Why It's Important?
The approval of Aquipta for acute migraine treatment is a significant development for patients who have limited options due to intolerance or lack of response to existing medications. This decision could improve the quality of life for many migraine sufferers by providing a new, effective treatment option. It also underscores the importance of continued innovation in migraine therapies, as Aquipta represents a new class of oral CGRP inhibitors that have transformed migraine management. The approval may also influence prescribing practices and healthcare policies regarding migraine treatment.
What's Next?
Following the approval, the focus will shift to ensuring that patients can access Aquipta through local commissioning by Integrated Care Boards. The Migraine Trust has highlighted the need for swift and consistent access to the drug in both primary and secondary care settings. Additionally, AbbVie is conducting further trials to explore the use of Aquipta for menstrual migraine prevention, with results expected later this year. These developments could lead to expanded indications and further regulatory filings in Europe and the US.
